CRIS
vs
S&P 500
CRIS
S&P 500
Over the past 12 months, CRIS has underperformed S&P 500, delivering a return of -68% compared to the S&P 500's +14% growth.
Stocks Performance
CRIS vs S&P 500
Performance Gap
CRIS vs S&P 500
Performance By Year
CRIS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Curis Inc
Glance View
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.